The EANO Winter School aims to provide an update on the recent advances in the pathogenesis and management of CNS tumors with particular attention devoted to the application in the clinical practice. The educational event will include lectures and case-based workshops, and is aimed to attract scientists, physicians and healthcare professionals involved in diagnosis and treatment of brain tumors.
The main target group are young EANO Youngsters, especially junior staff from all over Europe.
Date: March 15-16, 2024 (arrival Thursdays evening, Friday full day, Saturday until early afternoon)
Venue: Warsaw, Poland
further information will follow soon!
Neurosurgical resection is crucial in the multimodal treatment of brain metastases. However, no widely accepted guidelines for perioperative imaging for brain metastases are currently available to guide postoperative therapy. To optimize standardized management and adjuvant treatment decisions for patients with brain metastases on an international level the EANO Youngsters committee performed for the first-time an international survey via the EANO network. The aim of this study was to analyze the different perioperative imaging modalities applied at various neurooncological centers worldwide in patients with brain metastasis.
According to this survey, MRI was the preferred imaging method in the preoperative setting. In the postoperative course, imaging modalities and timing showed high variability. International guidelines for perioperative imaging with special focus on postoperative MRI to determine the extent of resection are warranted to optimize standardized management and adjuvant treatment decisions for patients with brain metastases.
Reference: Kiesel, B., Thomé, C.M., Weiss, T. et al. Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee. BMC Cancer 20, 410 (2020). doi: 10.1186/s12885-020-06897-z.
According to the EANO Youngsters
The EANO Youngsters selected the most important scientific neuro-oncology papers of 2019. Instead of just looking at the number of citations or impact factors, we performed a survey in our EANO Youngsters Facebook group. We received a lot of input! We now have an interesting impression of which studies our followers were most interested in this year.
This year's list features important basic science papers, published in high-impact journals, and possible practice-changing clinical papers.
So, here are our top 6 paper:
- Suva group's single cell paper: Neftel C. et al. (2019) An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 178(4):835-849.e21. doi: 10.1016/j.cell.2019.06.024. https://www.ncbi.nlm.nih.gov/pubmed/31327527
- The Nature-trio on synaptic interactions between glioma cells and neurons: Barrier A. Dangerous liaisons as tumour cells form synapses with neurons. Nature (2019) 573, 499-501, doi: 10.1038/d41586-019-02746-7 https://www.nature.com/articles/d41586-019-02746-7
- Taylor group's snRNA paper: Suzuki H. et al. . Recurrent non-coding U1-snRNA mutations drive cryptic splicing in Shh medulloblastoma. Nature. (2019). doi: 10.1038/s41586-019-1650-0. https://www.ncbi.nlm.nih.gov/pubmed/31597162
- Exciting work from the Glioma Longitudinal Analysis (GLASS) Consortium: Barthel, F.P., Johnson, K.C., Varn, F.S. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature (2019) doi:10.1038/s41586-019-1775-1 https://www.nature.com/articles/s41586-019-1775-1
- Whole brain radiotherapy with or without hippocampal avoidance in brain metastases: Tomé W. et al. RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM), Neuro-Oncology Advances, Volume 1, Issue Supplement_1, August 2019, Pages i23–i24, doi.org/10.1093/noajnl/vdz014.104 https://academic.oup.com/noa/article/1/Supplement_1/i23/5546283
- Lomustine-temozolomide or standard temozolomide therapy in glioblastoma: Herrlinger U. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet (2019) 393 (10172), P678-688, doi.org/10.1016/S0140-6736(18)31791-4 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31791-4/fulltext?dgcid=raven_jbs_etoc_email
The EANO Youngsters facebook group should help to interact with other youngsters more early. Exchange experience and information, ask for advise from the community and share interesting information e.g. on trials or papers. Not yet connected? Just enter “EANO Youngsters” and join the community!